On February 3, 2021, IncellDx, a leading precision medicine diagnostics company, announced that it had filed patents for algorithms identifying immunologic profiles unique to COVID long-haulers and patients with severe COVID. IncellDx has developed and patented two distinct algorithms using machine learning, built on a tailored panel of cytokines and chemokines specific for abnormalities in cytokine storm conditions and in chronic COVID patients (often referred to as COVID "long-haulers"). These have been submitted for publication (pre-print available through BioRxiv https://www.biorxiv.org/content/10.1101/2020.12.16.423122v1). The preprint is titled “Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.” The first algorithm generates a severity score based on analysis of hundreds of COVID-19 patients spanning the spectrum of disease severity from mild to critical. The second algorithm derived from the same cytokine/chemokine immune panel, demonstrates that the immunology of long-haulers is distinct from active COVID-19. This objective algorithm offers the opportunity for precision medicine to be used by physicians as a guide in the care of COVID-19 patients. Bruce Patterson, MD, CEO of IncellDx, commented that "Since the beginning of the COVID-19 pandemic, IncellDx has led the way in using biomarkers to develop precision medicine approaches to therapy including the post-COVID-19 long-haulers. A recent preprint of a meta-analysis suggests as many as 80% of individuals infected by COVID-19 may have at least one symptom long after infection." IncellDx, in collaboration with Ram Yogendra, MD, and Purvi Parikh, MD, launched the website http://www.covidlonghaulers.com on January 29, 2021.
Login Or Register To Read Full Story
